77774-35-7

Usage

InChI:InChI=1/C9H11NO2/c1-6-4-3-5-8(12)9(6)10-7(2)11/h3-5,12H,1-2H3,(H,10,11)

Upstream product

• 2835-97-4 2-amino-3-methylphenol 
• 108-24-7 acetic anhydride 

Downstream Products

• 384346-23-0 N-(2-Methyl-6-oxiranylmethoxy-phenyl)-acetamide 
• 1628201-96-6 C₁₂H₁₅NO₂ 
• 1247460-13-4 2-(allyloxy)-6-methylaniline 
• 1613169-87-1 C₁₅H₁₄BrNO₃ 
• 1613169-88-2 C₁₇H₁₅N₃O₃ 
• 1613169-83-7 C₁₄H₁₂BrNO₃ 
• 1591642-55-5 C₆₈H₈₄N₈O₉S₂ 
• 1591642-32-8 1-(6-(2-(3-([1,1'-biphenyl]-4-yl)-5-methyl-4H-1,2,4-triazol-4-yl)-3-methyl-phenoxy)hexyl)piperazine 
• 1591642-47-5 2-[2-[4-[6-[2-(3-([1,1'-biphenyl]-4-yl)-5-methyl-4H-1,2,4-triazol-4-yl)-3-methylphenoxy]hexyl]piperazin-1-yl]ethoxy]ethyl di(tert)butylimino-carboxylate 
• 133841-05-1 7-methoxy-1H-indazole 
• 81382-46-9 7-hydroxy-1H-indazole 
• 258878-32-9 5-(4-biphenyl)-4-(2-hydroxy-6-methylphenyl)-3-methyl-1,2,4-triazole 

Relevant academic research and scientific papers

Antimalarial Benzimidazole Derivatives Incorporating Phenolic Mannich Base Side Chains Inhibit Microtubule and Hemozoin Formation: Structure-Activity Relationship and in Vivo Oral Efficacy Studies

A novel series of antimalarial benzimidazole derivatives incorporating phenolic Mannich base side chains at the C2 position, which possess dual asexual blood and sexual stage activities, is presented. Structure-activity relationship studies revealed that the 1-benzylbenzimidazole analogues possessed submicromolar asexual blood and sexual stage activities in contrast to the 1H-benzimidazole analogues, which were only active against asexual blood stage (ABS) parasites. Further, the former demonstrated microtubule inhibitory activity in ABS parasites but more significantly in stage II/III gametocytes. In addition to being bona fide inhibitors of hemozoin formation, the 1H-benzimidazole analogues also showed inhibitory effects on microtubules. In vivo efficacy studies in Plasmodium berghei-infected mice revealed that the frontrunner compound 41 exhibited high efficacy (98% reduction in parasitemia) when dosed orally at 4 × 50 mg/kg. Generally, the compounds were noncytotoxic to mammalian cells.

Tailoring atropisomeric maleimides for stereospecific [2 + 2] photocycloaddition-photochemical and photophysical investigations leading to visible-light photocatalysis

Atropisomeric maleimides were synthesized and employed for stereospecific [2 + 2] photocycloaddition. Efficient reaction was observed under direct irradiation, triplet-sensitized UV irradiation, and non-metal catalyzed visible-light irradiation, leading to two regioisomeric (exo/endo) photoproducts with complete chemoselectivity (exclusive [2 + 2] photoproduct). High enantioselectivity (ee > 98%) and diastereoselectivity (dr > 99:1%) were observed under the employed reaction conditions and were largely dependent on the substituent on the maleimide double bond but minimally affected by the substituents on the alkenyl tether. On the basis of detailed photophysical studies, the triplet energies of the maleimides were estimated. The triplet lifetimes appeared to be relatively short at room temperature as a result of fast [2 + 2] photocycloaddition. For the visible-light mediated reaction, triplet energy transfer occurred with a rate constant close to the diffusion-limited value. The mechanism was established by generation of singlet oxygen from the excited maleimides. The high selectivity in the photoproduct upon reaction from the triplet excited state was rationalized on the basis of conformational factors as well as the type of diradical intermediate that was preferred during the photoreaction.

Labeled ligands of the oxytocyn receptor

The invention relates to compounds of formula: wherein L and A are as defined in the description. These compounds can be used as ligands of the oxytocin receptor.

LABELED LIGANDS OF THE OXYTOCIN RECEPTOR

The invention relates to compounds of formula (I) wherein L and A are as defined in the description. These compounds can be used as ligands of the oxytocin receptor.

Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V1a receptor

A series of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives were prepared and evaluated as selective antagonists for the human vasopressin V1A receptor. The compounds were examined for their affinity to the cloned human V1A receptor (hV1A) and selectivity vs the cloned human V2 receptor (hV2). By utilizing the structure-activity relationship on 4,4-difluoro-5-methylidene-2,3,4,5-tetrahydrobenzazepine derivatives as dual antagonists for the V1A and V2 receptors in our previous study, we found that substituting the methoxy group at the 2-position of the 4-phenyl ring with (4-methylpiperazin-1-yl)alkoxy moieties brought about marked improvement of both affinity to hV1A and selectivity vs hV2. Further introduction of a methyl group into the 6-position of the 4-phenyl ring resulted in additional improvement of selectivity. One particular compound, 5-(4-biphenyl)-3-methyl-4-{2-[6-(4-methyl-l-piperazinyl)-hexyloxy]phenyl} -1,2,4-triazole (19) showed potent affinity to hV1A with a Ki value of 1.04 nM and high selectivity with a 1700-fold selectivity vs hV2. We also found marked differences in the affinity of compounds in this series between the human and the rat receptors. Compound, 19 was further examined for its V1A receptor antagonist activity in rats. As a result, 19 demonstrated antagonist activities toward an arginine vasopressin-induced increase in diastolic blood pressure after intravenous or oral administration and long-lasting oral activity.